Reason for request
Inclusion
-
Clinical Benefit
Substantial |
The Committee considers that the actual benefit of the proprietary medicinal product TADIM in the Marketing Authorisation indication is : - substantial within the context of its administration with a "conventional" nebuliser system requiring a pneumatic generator (Pari LC system). |
Insufficient |
- insufficient within the context of its administration with theportable nebuliser system fitted with "AAD" and "VMT" (I neb AAD system) technologies or the Respironics Sidestream system with a Portaneb compressor. |
Clinical Added Value
no clinical added value |
TADIM does not provide an improvement in actual benefit (IAB V,non-existent) compared with COLIMYCIN 1 MIU nebuliser solution. |